


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:


**Listing of Claims:**

1. (Amended) A compound having the following structure:



including stereoisomers and pharmaceutically acceptable salts thereof,

wherein:



~~represents  $\text{N}=\text{CH}-$ ,  $\text{NH}-\text{CH}_2-$  or  $\text{NH}-(\text{CH}_2)_2-$~~

~~X is N or  $\text{CR}_3$~~ ;

R<sub>1</sub> is  $-\text{CH}(\text{R}_4)(\text{R}_5)$ ;

R<sub>2</sub> is C<sub>1-6</sub>alkyl;

R<sub>3</sub> is hydrogen or C<sub>1-6</sub>alkyl;

R<sub>4</sub> is hydrogen, C<sub>1-6</sub>alkyl, mono- or di(C<sub>3-6</sub>cycloalkyl)methyl, C<sub>3-6</sub>cycloalkyl, C<sub>3-6</sub>alkenyl, hydroxyC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylcarbonyloxyC<sub>1-6</sub>alkyl, or C<sub>1-6</sub>alkyloxyC<sub>1-6</sub>alkyl, and


R<sub>5</sub> is C<sub>1-8</sub>alkyl, mono- or di(C<sub>3-6</sub>cycloalkyl)methyl, Ar<sup>1</sup>CH<sub>2</sub>, C<sub>3-6</sub>alkenyl, C<sub>1-6</sub>alkyloxyC<sub>1-6</sub>alkyl, hydroxyC<sub>1-6</sub>alkyl, thienylmethyl, furanylmethyl, C<sub>1-6</sub>alkylthioC<sub>1-6</sub>alkyl, morpholinyl, mono- or di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl, di(C<sub>1-6</sub>alkyl)amino, C<sub>1-6</sub>alkylcarbonylC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl substituted with imidazolyl, -CH<sub>2</sub>Obenzyl, or a radical of the formula -(C<sub>1-6</sub>alkanediyl)-O-CO-Ar<sup>1</sup>,

or R<sub>4</sub> and R<sub>5</sub> taken together with the carbon atom to which they are bonded form a C<sub>5-8</sub>cycloalkyl optionally substituted with one or more substituents independently selected from C<sub>1-6</sub>alkyl;

Ar is phenyl substituted with 1, 2 or 3 substituents independently selected from halo, C<sub>1-6</sub>alkyl, trifluoromethyl, cyano, C<sub>1-6</sub>alkyloxy, benzyloxy, C<sub>1-6</sub>alkylthio, nitro, amino, and mono- or di(C<sub>1-6</sub>alkyl)amino; or an aromatic C<sub>3-12</sub>heterocycle optionally substituted with 1, 2 or 3 substituents independently selected from halo, C<sub>1-6</sub>alkyl, trifluoromethyl, hydroxy, cyano, C<sub>1-6</sub>alkyloxy, benzyloxy, C<sub>1-6</sub>alkylthio, nitro, amino, mono- or di(C<sub>1-6</sub>alkyl)amino, and piperidinyl; and


Ar<sup>1</sup> is phenyl, pyridinyl, or phenyl substituted with 1, 2 or 3 substituents independently selected from halo, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyloxy, di(C<sub>1-6</sub>alkyl)aminoC<sub>1-6</sub>alkyl, trifluoromethyl and C<sub>1-6</sub>alkyl substituted with morpholinyl.

2. (Amended) The compound of claim 1 having the structure:



3. (Canceled)

4. (Amended) The compound of claim 1 having the structure:



5.-7. (Canceled)

8. (Original) The compound of claim 1 wherein Ar is 2,4-dichlorophenyl.

9. (Original) The compound of claim 1 wherein Ar is 2-chloro-4-methylphenyl.

10. (Original) The compound of claim 1 wherein Ar is 2-methyl-4-chlorophenyl.

11. (Original) The compound of claim 1 wherein Ar is 2,4,6-trimethylphenyl.

12. (Original) The compound of claim 1 wherein Ar is 2-chloro-4-methoxyphenyl.

13. (Original) The compound of claim 1 wherein Ar is 2-methyl-4-methoxyphenyl.

14. (Original) The compound of claim 1 wherein Ar is 2,4-dimethoxy-phenyl.
15. (Original) The compound of claim 1 wherein Ar is 4-dimethylamino-2-methyl-3-pyridyl.
16. (Original) The compound of claim 1 wherein Ar is 4-dimethylamino-6-methyl-3-pyridyl.
17. (Original) The compound of claim 1 wherein Ar is 4-dimethylamino-3-pyridyl.
18. (Original) The compound of claim 1 wherein R<sub>1</sub> is -CH(n-propyl)<sub>2</sub>.
19. (Original) The compound of claim 1 wherein R<sub>1</sub> is -CH(n-propyl)(CH<sub>2</sub>OCH<sub>3</sub>).
20. (Original) The compound of claim 1 wherein R<sub>1</sub> is -CH(benzyl)(CH<sub>2</sub>OCH<sub>3</sub>).
21. (Original) The compound of claim 1 wherein R<sub>1</sub> is -CH(CH<sub>2</sub>OR)<sub>2</sub> and each occurrence of R is independently selected from C<sub>1-6</sub>alkyl.
22. (Original) The compound of claim 1 wherein R<sub>1</sub> is -CH(CH<sub>2</sub>OR)(ethyl) and each occurrence of R is independently selected from C<sub>1-6</sub>alkyl.
23. (Original) The compound of claim 1 wherein R<sub>1</sub> is -CH(CH<sub>2</sub>OR)(n-butyl) and each occurrence of R is independently selected from C<sub>1-6</sub>alkyl.

24. (Original) The compound of claim 1 wherein R<sub>1</sub> is -CH(CH<sub>2</sub>OR)(tert-butyl) and each occurrence of R is independently selected from C<sub>1-6</sub>alkyl.

25. (Original) The compound of claim 1 wherein R<sub>1</sub> is -CH(CH<sub>2</sub>OR)(4-chloro-benzyl) and each occurrence of R is independently selected from C<sub>1-6</sub>alkyl.

26. (Original) The compound of claim 1 wherein R<sub>1</sub> is -CH(CH<sub>2</sub>OR)(CH<sub>2</sub>CH<sub>2</sub>SCH<sub>3</sub>) and each occurrence of R is independently selected from C<sub>1-6</sub>alkyl.

27. (Original) The compound of claim 1 wherein R<sub>1</sub> is -CH(CH<sub>2</sub>CH<sub>3</sub>)(CH<sub>2</sub>Obenzyl).

28. (Original) The compound of claim 1 wherein R<sub>2</sub> is methyl.

29. (Original) The compound of claim 1 wherein R<sub>2</sub> is ethyl.

30. (Amended) A pharmaceutical composition comprising a compound of claim 1 in combination with a pharmaceutically acceptable carrier or diluent.

31. (Amended) A method for treating stroke, anxiety, depression or irritable bowel syndrome ~~a disorder manifesting hypersecretion of CRF~~ in a warm-blooded animal, comprising administering to the animal an effective amount of the pharmaceutical composition of claim 30.

32. (Original) The method of claim 31 wherein the disorder is stroke.

33. (Original) The method of claim 31 wherein the disorder is anxiety.

---

34. (Original) The method of claim 31 wherein the disorder is depression.

35. (Original) The method of claim 31 wherein the disorder is irritable bowel syndrome.